<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26593938</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.</ArticleTitle><Pagination><StartPage>5919</StartPage><EndPage>5932</EndPage><MedlinePgn>5919-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/v7112916</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) has recently emerged as a major public health concern across the Asian-Pacific region. Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) are the primary causative agents of HFMD, but other members of the Enterovirus A species, including Coxsackievirus A6 (CVA6), can cause disease. The lack of small animal models for these viruses have hampered the development of a licensed HFMD vaccine or antivirals. We have previously reported on the development of a mouse model for EV71 and demonstrated the protective efficacy of an inactivated EV71 vaccine candidate. Here, mouse-adapted strains of CVA16 and CVA6 were produced by sequential passage of the viruses through mice deficient in interferon (IFN) &#x3b1;/&#x3b2; (A129) and &#x3b1;/&#x3b2; and &#x3b3; (AG129) receptors. Adapted viruses were capable of infecting 3 week-old A129 (CVA6) and 12 week-old AG129 (CVA16) mice. Accordingly, these models were used in active and passive immunization studies to test the efficacy of a trivalent vaccine candidate containing inactivated EV71, CVA16, and CVA6. Full protection from lethal challenge against EV71 and CVA16 was observed in trivalent vaccinated groups. In contrast, monovalent vaccinated groups with non-homologous challenges failed to cross protect. Protection from CVA6 challenge was accomplished through a passive transfer study involving serum raised against the trivalent vaccine. These animal models will be useful for future studies on HFMD related pathogenesis and the efficacy of vaccine candidates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caine</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA. ecaine@wisc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuchs</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Takeda Vaccines Inc., Madison, WI 53719, USA. jeremy.fuchs@takeda.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Subash C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Takeda Vaccines Inc., Madison, WI 53719, USA. subash.das@takeda.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Partidos</LastName><ForeName>Charalambos D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Takeda Vaccines Inc., Madison, WI 53719, USA. harry.partidos@takeda.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osorio</LastName><ForeName>Jorge E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA. jorge.osorio@wisc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Takeda Vaccines Inc., Madison, WI 53719, USA. jorge.osorio@wisc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000220" MajorTopicYN="N">Adaptation, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056738" MajorTopicYN="N">Cross Protection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012692" MajorTopicYN="N">Serial Passage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AG129 mice</Keyword><Keyword MajorTopicYN="N">Coxsackievirus A16</Keyword><Keyword MajorTopicYN="N">Coxsackievirus A6</Keyword><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword><Keyword MajorTopicYN="N">trivalent vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26593938</ArticleId><ArticleId IdType="pmc">PMC4664989</ArticleId><ArticleId IdType="doi">10.3390/v7112916</ArticleId><ArticleId IdType="pii">v7112916</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chong P., Liu C.C., Chow Y.H., Chou A.H., Klein M. Review of enterovirus 71 vaccines. Clin. Infect. Dis. 2015;60:797&#x2013;803. doi: 10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterback R., Vuorinen T., Linna M., Susi P., Hyypia T., Waris M. Coxsackievirus a6 and hand, foot, and mouth disease, finland. Emerg. Infect. Dis. 2009;15:1485&#x2013;1488. doi: 10.3201/eid1509.090438.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1509.090438</ArticleId><ArticleId IdType="pmc">PMC2819858</ArticleId><ArticleId IdType="pubmed">19788821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M., el Khatib N.F., Tu S., Ren P., Xu S., Zhu Q., Mo X., Pu D., Wang X., Altmeyer R. Seroepidemiology of enterovirus 71 infection prior to the 2011 season in children in Shanghai. J. Clin. Virol. 2012;53:285&#x2013;289. doi: 10.1016/j.jcv.2011.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.12.025</ArticleId><ArticleId IdType="pubmed">22265829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen N.T., Pham H.V., Hoang C.Q., Nguyen T.M., Nguyen L.T., Phan H.C., Phan L.T., Vu L.N., Tran Minh N.N. Epidemiological and clinical characteristics of children who died from hand, foot and mouth disease in Vietnam, 2011. BMC Infect. Dis. 2014;14:341. doi: 10.1186/1471-2334-14-341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-341</ArticleId><ArticleId IdType="pmc">PMC4068316</ArticleId><ArticleId IdType="pubmed">24942066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Yeo A., Phoon M.C., Tan E.L., Poh C.L., Quak S.H., Chow V.T. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int. J. Infect. Dis. 2010;14:e1076&#x2013;e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyoshi K., Suga T., Mori A. Enteroviruses in patients experiencing multiple episodes of hand, foot, and mouth disease in the same season in Kobe, Japan, 2011. Jpn. J. Infect. Dis. 2012;65:459&#x2013;461. doi: 10.7883/yoken.65.459.</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.65.459</ArticleId><ArticleId IdType="pubmed">22996228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.J., Kim J.H., Kang J.H., Kim D.S., Kim K.H., Kim K.H., Kim Y.H., Chung J.Y., Bin J.H., Jung da E., et al. Risk factors for neurologic complications of hand, foot and mouth disease in the Republic of Korea, 2009. J. Korean Med. Sci. 2013;28:120&#x2013;127. doi: 10.3346/jkms.2013.28.1.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2013.28.1.120</ArticleId><ArticleId IdType="pmc">PMC3546090</ArticleId><ArticleId IdType="pubmed">23341722</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca M.C., Sarmiento L., Resik S., Martinez Y., Hung L.H., Morier L., Pinon A., Valdez O., Kouri V., Gonzalez G. Coxsackievirus a6 and enterovirus 71 causing hand, foot and mouth disease in Cuba, 2011&#x2013;2013. Arch Virol. 2014;159:2451&#x2013;2455. doi: 10.1007/s00705-014-2071-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-014-2071-x</ArticleId><ArticleId IdType="pubmed">24719197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrerizo M., Tarrago D., Munoz-Almagro C., del Amo E., Dominguez-Gil M., Eiros J.M., Lopez-Miragaya I., Perez C., Reina J., Otero A., et al. Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain. Clin. Microbiol. Infect. 2014;20:O150&#x2013;O156. doi: 10.1111/1469-0691.12361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12361</ArticleId><ArticleId IdType="pubmed">24033818</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.W., Liu C.C., Lu T.C., Liu S.J., Chow Y.H., Chong P., Huang M.H. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. BioMed Res. Int. 2014;2014:670506. doi: 10.1155/2014/670506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/670506</ArticleId><ArticleId IdType="pmc">PMC4071850</ArticleId><ArticleId IdType="pubmed">25006583</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W.C., Huang L.M., Kao C.L., Lu C.Y., Shao P.L., Cheng A.L., Fan T.Y., Chi H., Chang L.Y. Seroprevalence of enterovirus 71 and no evidence of crossprotection of enterovirus 71 antibody against the other enteroviruses in kindergarten children in Taipei city. J. Microbiol. Immunol. Infect. 2012;45:96&#x2013;101. doi: 10.1016/j.jmii.2011.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2011.09.025</ArticleId><ArticleId IdType="pubmed">22154997</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., Zhang Y., Li Y., Mao Q., Wang J., et al. An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 2014;370:829&#x2013;837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., Zhang Y.T., Yao X., Chu K., Chen Q.H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in china: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Cheng T., Zhu F., Li J., Wang Y., Li Y., Gao F., Yang L., Yao X., Shao J., et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS ONE. 2013;8:e79599. doi: 10.1371/journal.pone.0079599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079599</ArticleId><ArticleId IdType="pmc">PMC3834186</ArticleId><ArticleId IdType="pubmed">24260259</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Chow Y.H., Chong P., Klein M. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine. 2014;32:6177&#x2013;6182. doi: 10.1016/j.vaccine.2014.08.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.08.064</ArticleId><ArticleId IdType="pubmed">25218294</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Chang J., Liu X., Yang J., Guo H., Wei W., Zhang W., Yu X.F. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J. Gen. Virol. 2014;95:1083&#x2013;1093. doi: 10.1099/vir.0.063560-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.063560-0</ArticleId><ArticleId IdType="pmc">PMC3983757</ArticleId><ArticleId IdType="pubmed">24496826</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Ku Z., Liu Q., Leng Q., Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus a16 elicits balanced protective immunity against both viruses. Vaccine. 2014;32:2406&#x2013;2412. doi: 10.1016/j.vaccine.2014.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.03.012</ArticleId><ArticleId IdType="pubmed">24657161</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Duo J., Liu J., Ma C., Zhang L., Wei Q., Qin C. A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect. 2011;13:862&#x2013;870. doi: 10.1016/j.micinf.2011.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2011.04.004</ArticleId><ArticleId IdType="pubmed">21612764</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.C., Yu C.K., Wang Y.F., Liu C.C., Su I.J., Lei H.Y. A murine oral enterovirus 71 infection model with central nervous system involvement. J. Gen. Virol. 2004;85:69&#x2013;77. doi: 10.1099/vir.0.19423-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.19423-0</ArticleId><ArticleId IdType="pubmed">14718621</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong W.X., Yan B., Yeo H., Tan E.L., Lee J.J., Ng J.K., Chow V.T., Alonso S. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J. Virol. 2012;86:2121&#x2013;2131. doi: 10.1128/JVI.06103-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06103-11</ArticleId><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.F., Chou C.T., Lei H.Y., Liu C.C., Wang S.M., Yan J.J., Su I.J., Wang J.R., Yeh T.M., Chen S.H., et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J. Virol. 2004;78:7916&#x2013;7924. doi: 10.1128/JVI.78.15.7916-7924.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.7916-7924.2004</ArticleId><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao P.P., Qian L., Xia Y., Xu F., Yang Z.N., Xie R.H., Li X., Liang W.F., Huang X.X., Zhu Z.Y., et al. Enterovirus 71-induced neurological disorders in young gerbils, meriones unguiculatus: Development and application of a neurological disease model. PLoS ONE. 2012;7:e51996. doi: 10.1371/journal.pone.0051996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0051996</ArticleId><ArticleId IdType="pmc">PMC3528719</ArticleId><ArticleId IdType="pubmed">23284845</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K., Nagata N., Sato Y., Ong K.C., Wong K.T., Yamayoshi S., Shimanuki M., Shitara H., Taya C., Koike S. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc. Natl. Acad. Sci. USA. 2013;110:14753&#x2013;14758. doi: 10.1073/pnas.1217563110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Li S., Liu Y., Hou W., Lin Q., Zhao H., Xu L., He D., Ye X., Zhu H., et al. Construction and characterization of an infectious clone of coxsackievirus A6 that showed high virulence in neonatal mice. Virus Res. 2015;210:165&#x2013;168. doi: 10.1016/j.virusres.2015.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2015.08.002</ArticleId><ArticleId IdType="pubmed">26272672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Wang Y., Gao R., Shao J., Yao X., Lang S., Wang C., Mao P., Liang Z., Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J. Virol. 2012;86:11967&#x2013;11976. doi: 10.1128/JVI.00902-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00902-12</ArticleId><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch L.E., Zellweger R.M., Kotturi M.F., Qutubuddin A., Sidney J., Peters B., Prestwood T.R., Sette A., Shresta S. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 2009;182:4865&#x2013;4873. doi: 10.4049/jimmunol.0801974.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0801974</ArticleId><ArticleId IdType="pmc">PMC2674070</ArticleId><ArticleId IdType="pubmed">19342665</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch L.E., Prestwood T.R., May M.M., Morar M.M., Zellweger R.M., Peters B., Sette A., Shresta S. Cd4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J. Immunol. 2010;185:5405&#x2013;5416. doi: 10.4049/jimmunol.1001709.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001709</ArticleId><ArticleId IdType="pmc">PMC2962919</ArticleId><ArticleId IdType="pubmed">20870934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zompi S., Santich B.H., Beatty P.R., Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J. Immunol. 2012;188:404&#x2013;416. doi: 10.4049/jimmunol.1102124.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102124</ArticleId><ArticleId IdType="pmc">PMC3244532</ArticleId><ArticleId IdType="pubmed">22131327</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson A.J., Roehrig J.T. New mouse model for Dengue virus vaccine testing. J. Virol. 1999;73:783&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC103889</ArticleId><ArticleId IdType="pubmed">9847388</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewoo J.N., Kinney R.M., Powell T.D., Arguello J.J., Silengo S.J., Partidos C.D., Huang C.Y., Stinchcomb D.T., Osorio J.E. Immunogenicity and efficacy of chimeric Dengue vaccine (Denvax) formulations in interferon-deficient AG129 mice. Vaccine. 2012;30:1513&#x2013;1520. doi: 10.1016/j.vaccine.2011.11.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.11.072</ArticleId><ArticleId IdType="pmc">PMC4592107</ArticleId><ArticleId IdType="pubmed">22178727</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine E.A., Partidos C.D., Santangelo J.D., Osorio J.E. Adaptation of enterovirus 71 to adult interferon deficient mice. PLoS ONE. 2013;8:e59501. doi: 10.1371/journal.pone.0059501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0059501</ArticleId><ArticleId IdType="pmc">PMC3602422</ArticleId><ArticleId IdType="pubmed">23527208</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwa S.H., Lee Y.A., Brewoo J.N., Partidos C.D., Osorio J.E., Santangelo J.D. Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine. PLoS Negl. Trop. Dis. 2013;7:e2538. doi: 10.1371/journal.pntd.0002538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002538</ArticleId><ArticleId IdType="pmc">PMC3820736</ArticleId><ArticleId IdType="pubmed">24244774</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaunt E., Harvala H., Osterback R., Sreenu V.B., Thomson E., Waris M., Simmonds P. Genetic characterization of human coxsackievirus a6 variants associated with atypical hand, foot and mouth disease: A potential role of recombination in emergence and pathogenicity. J. Gen. Virol. 2015;96:1067&#x2013;1079. doi: 10.1099/vir.0.000062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.000062</ArticleId><ArticleId IdType="pmc">PMC4631059</ArticleId><ArticleId IdType="pubmed">25614593</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttery V.W., Kenyon C., Grunewald S., Oberste M.S., Nix W.A. Notes from the field: Atypical presentations of hand, foot, and mouth disease caused by coxsackievirus A6&#x2014;Minnesota, 2014. MMWR. 2015;64:805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584838</ArticleId><ArticleId IdType="pubmed">26225481</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Shimizu H. Cellular receptors for human enterovirus species A. Front. Microbiol. 2012;3:105. doi: 10.3389/fmicb.2012.00105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2012.00105</ArticleId><ArticleId IdType="pmc">PMC3313065</ArticleId><ArticleId IdType="pubmed">22470371</ArticleId></ArticleIdList></Reference><Reference><Citation>Feder H.M., Jr., Bennett N., Modlin J.F. Atypical hand, foot, and mouth disease: A vesiculobullous eruption caused by coxsackie virus A6. Lancet Infect. Dis. 2014;14:83&#x2013;86. doi: 10.1016/S1473-3099(13)70264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70264-0</ArticleId><ArticleId IdType="pubmed">24287184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lott J.P., Liu K., Landry M.L., Nix W.A., Oberste M.S., Bolognia J., King B. Atypical hand-foot-and-mouth disease associated with coxsackievirus A6 infection. J. Am. Acad. Dermatol. 2013;69:736&#x2013;741. doi: 10.1016/j.jaad.2013.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2013.07.024</ArticleId><ArticleId IdType="pmc">PMC5843477</ArticleId><ArticleId IdType="pubmed">24035209</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S.L., Pan H., Liu P., Amer S., Chan T.C., Zhan J., Huo X., Liu Y., Teng Z., Wang L., et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev. Med. Virol. 2015;25:115&#x2013;128. doi: 10.1002/rmv.1827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1827</ArticleId><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Liang Z.L., Li X.L., Ge H.M., Meng F.Y., Mao Q.Y., Zhang Y.T., Hu Y.M., Zhang Z.Y., Li J.X., et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2013;381:1037&#x2013;1045. doi: 10.1016/S0140-6736(12)61764-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61764-4</ArticleId><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Penaranda S., Maher K., Pallansch M.A. Complete genome sequences of all members of the species human enterovirus A. J. Gen. Virol. 2004;85:1597&#x2013;1607. doi: 10.1099/vir.0.79789-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79789-0</ArticleId><ArticleId IdType="pubmed">15166444</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong M., Zhu H., Zhou J., Yang C., Feng J., Huang X., Ji G., Xu H., Zhu P. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus A16 virus-like particles provides a structural basis for vaccine development. J. Virol. 2014;88:6444&#x2013;6452. doi: 10.1128/JVI.00200-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00200-14</ArticleId><ArticleId IdType="pmc">PMC4093858</ArticleId><ArticleId IdType="pubmed">24672036</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Cardosa J., Kuhn R.J., Rossmann M.G. Crystal structure of human enterovirus 71. Science. 2012;336:1274. doi: 10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J., Wang X., Hu Z., Gao Q., Sun Y., Li X., Porta C., Walter T.S., Gilbert R.J., Zhao Y., et al. Picornavirus uncoating intermediate captured in atomic detail. Nat. Commun. 2013;4:1929. doi: 10.1038/ncomms2889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2889</ArticleId><ArticleId IdType="pmc">PMC3709478</ArticleId><ArticleId IdType="pubmed">23728514</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G., Ang R.X., Alonso S., Chow V.T., Quak S.H., Poh C.L. Identification of immunodominant VP1 linear epitope of enterovirus 71 (EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in western blots. Clin. Microbiol. Infect. 2008;14:286&#x2013;288. doi: 10.1111/j.1469-0691.2007.01904.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2007.01904.x</ArticleId><ArticleId IdType="pubmed">18076666</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim X.F., Jia Q., Khong W.X., Yan B., Premanand B., Alonso S., Chow V.T., Kwang J. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS ONE. 2012;7:e29751. doi: 10.1371/journal.pone.0029751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0029751</ArticleId><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T.K., Jia Q., Meng T., Chow V.T., Kwang J. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved &#x201c;knob&#x201d; region of VP3 protein. PLoS Negl. Trop. Dis. 2014;8:e2895. doi: 10.1371/journal.pntd.0002895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002895</ArticleId><ArticleId IdType="pmc">PMC4038473</ArticleId><ArticleId IdType="pubmed">24875055</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Huang X., Liu Q., Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013;31:2130&#x2013;2136. doi: 10.1016/j.vaccine.2013.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.051</ArticleId><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Yang L., Li Z., Ye X., Yu H., zhao H., Li S., Yuan L., Qian H., et al. A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci. Rep. 2015;5:12973. doi: 10.1038/srep12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12973</ArticleId><ArticleId IdType="pmc">PMC4525384</ArticleId><ArticleId IdType="pubmed">26243660</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Li H.Y., Han J.F., Deng Y.Q., Zhu S.Y., Li X.F., Yang H.Q., Li Y.X., Zhang Y., Qin E.D., et al. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Sci. Rep. 2015;5:7878. doi: 10.1038/srep07878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07878</ArticleId><ArticleId IdType="pmc">PMC4297979</ArticleId><ArticleId IdType="pubmed">25597595</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Xu Y., Qiao L., Wang Y., Wu X., Fan D., Peng Q., Xu X. Trivalent human papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine. 2010;28:3479&#x2013;3487. doi: 10.1016/j.vaccine.2010.02.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.02.057</ArticleId><ArticleId IdType="pubmed">20211219</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>